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Abstract
Background: Hyperglycemia has been associated with unfavorable outcome in several disorders, but few data
are available in bacterial meningitis. We assessed the incidence and significance of hyperglycemia in adults with
bacterial meningitis.
Methods: We collected data prospectively between October 1998 and April 2002, on 696 episodes of
community-acquired bacterial meningitis, confirmed by culture of CSF in patients >16 years. Patients were
dichotomized according to blood glucose level on admission. A cutoff random non-fasting blood glucose level of
7.8 mmol/L (140 mg/dL) was used to define hyperglycemia, and a cutoff random non-fasting blood glucose level
of 11.1 mmol/L (200 mg/dL) was used to define severe hyperglycemia. Unfavorable outcome was defined on the
Glasgow outcome scale as a score <5. We also evaluated characteristics of patients with a preadmission diagnosis
of diabetes mellitus.
Results: 69% of patients were hyperglycemic and 25% severely hyperglycemic on admission. Compared with non-
hyperglycemic patients, hyperglycemia was related with advanced age (median, 55 yrs vs. 44 yrs, P < 0.0001),
preadmission diagnosis of diabetes (9% vs. 3%, P = 0.005), and distant focus of infection (37% vs. 28%, P = 0.02).
They were more often admitted in coma (16% vs. 8%; P = 0.004) and with pneumococcal meningitis (55% vs. 42%,
P = 0.007). These differences remained significant after exclusion of patients with known diabetes. Hyperglycemia
was related with unfavorable outcome in a univariate analysis but this relation did not remain robust in a
multivariate analysis. Factors predictive for neurologic compromise were related with higher blood glucose levels,
whereas factors predictive for systemic compromise were related with lower blood glucose levels. Only a
minority of severely hyperglycemic patients were known diabetics (19%). The vast majority of these known
diabetic patients had meningitis due to Streptococcus pneumoniae (67%) or Listeria monocytogenes (13%) and they
were at high risk for unfavorable outcome (52%).
Conclusion: The majority of patients with bacterial meningitis have hyperglycemic blood glucose levels on
admission. Hyperglycemia can be explained by a physical stress reaction, the central nervous system insult leading
to disturbed blood-glucose regulation mechanisms, and preponderance of diabetics for pneumococcal meningitis.
Patients with diabetes and bacterial meningitis are at high risk for unfavorable outcome.
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Hyperglycemia has been reported to be associated with
poor outcome in several infectious and neurological dis-
orders, such as sepsis, stroke and severe head injury. [1-4]
In bacterial meningitis, one study showed no association
between hyperglycemia on admission and mortality, but
this study was retrospective and involved low numbers of
patients.[5] Acute hyperglycemia has been associated with
an increase of circulating cytokine concentrations and
with an impaired ability to oppose infection.[6] Intensive
insulin therapy has shown to prevent morbidity and
reduce mortality in critically ill patients.[7,8] In addition,
it has been shown to have strong anti-inflammatory
effects which could be of potential importance in patients
with severe bacterial meningitis.[9]
In this nationwide prospective cohort study we assessed
the prevalence and prognostic value of hyperglycemia on
admission in patients presenting with community-
acquired bacterial meningitis. We also evaluated charac-
teristics of patients with a preadmission diagnosis of dia-
betes mellitus.
Methods
The Dutch Meningitis Cohort Study is a prospective
nationwide observational cohort study of 696 adults with
community-acquired bacterial meningitis in the Nether-
lands, carried out between October 1998 and April 2002.
Inclusion and exclusion criteria have been described
extensively elsewhere.[10] In summary, all patients were
aged over 16 years and had cerebrospinal fluid (CSF) cul-
ture proven bacterial meningitis. In total, 696 episodes of
community-acquired bacterial meningitis occurred in 671
patients; 25 patients had a second episode of bacterial
meningitis. Informed consent was obtained from partici-
pating patients or their legally authorized representatives.
Information, including blood glucose values, was col-
lected by means of a case record form. Neurological exam-
ination was performed on discharge and the patient's
outcome was classified as unfavorable (defined by a Glas-
gow Outcome Scale score of 1 to 4 points at discharge) or
favorable (a score of 5).[10,11] The Glasgow Outcome
Scale is a well-validated measurement scale with scores
varying from 1 (indicating death) to 5 (good recov-
ery).[12] The study was performed in accordance with the
Dutch privacy legislation and was approved by our ethics
committee. Written informed consent to use data made
anonymous was obtained from the patient (if possible) or
from the patient's legal representative.
The criteria of the American Diabetes Association were
used to define hyperglycemia in non-fasting blood sam-
ples.[13] In these guidelines non-fasting blood glucose
levels of >7.8 mmol/L (>140 mg/dL) are defined as
"hyperglycemia" and ≥ 11.1 mmol/L (>200 mg/dL) as
diabetic values (in our paper referred to as "severe hyper-
glycemia"). We did not measure glycosylated hemoglobin
(HbA1C) in our patients and had no information on for-
mal glucose tolerance testing.
For the comparison of non-normally distributed variables
nonparametric testing, Mann-Whitney U, χ2, or Fisher
exact tests were used. We used logistic regression analysis
to calculate OR and 95% CI to assess the strength of the
association between potential risk factors and unfavorable
outcome or hyperglycemia. Based on previous research
and pathophysiological interest, 10 most relevant risk fac-
tors for outcome or blood glucose levels were
selected.[14] Although the median percentage of missing
values for individual variables in our study was low (2%),
data were complete on all potential predictors in 408 out
of 696 episodes (59%). Complete case analysis would
potentially hamper the power of the multivariate models
and, in addition, might lead to biased results. Therefore,
we used the multiple imputation method to replace each
missing value with a set of plausible values that represent
the uncertainty about the right value to impute. By repeat-
ing this process several times, the uncertainty in the preci-
sion is properly taken into account.[15] The final
estimates of the multivariate model were obtained by
combining the results of 10 rounds of imputations. Anal-
yses were also performed on the non-imputed dataset; in
all presented analyses point estimates were similar as
using the nonimputed dataset, with somewhat wider con-
fidence intervals. Population description is done with
medians and interquartile ranges (IQR). All analyses were
performed using SAS software, version 9.11 (SAS Insti-
tute) and a 2-tailed P value below 0.05 was considered as
significant.
Results
Serum blood glucose levels were measured on admission
in 682 of 696 episodes (98%). Hyperglycemia was present
in 470 episodes (69%; Table 1), including severe hyperg-
lycemia in 171 (25%). Two patients had a blood glucose
level <4 mmol/L (<72 mg/dL); both patients had a
preadmission diagnosis of diabetes. Patients with hyperg-
lycemia were older than non-hyperglycemic patients and
were more likely to have a preadmission diagnosis of dia-
betes. On the other hand, only a minority of the severely
hyperglycemic patients were known diabetics (19%).
Before admission, seizures were more often present
among hyperglycemic patients as compared with non-
hyperglycemic patients; however, this was not true for
severe hyperglycemia.
On admission, patients with hyperglycemia were more
likely to have a distant focus of infection (Table 1), mainly
otitis or sinusitis. When patients with a preadmission
diagnosis of diabetes were excluded, no association wasPage 2 of 7
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was such an association for severely hyperglycemic
patients (P = 0.004). Patients with hyperglycemia were
more likely to present with a change in mental status or in
a coma. This difference remained significant after exclu-
sion of diabetic patients (change in mental status: 72% vs.
60%, P = 0.003). Lumbar puncture was performed in all
episodes and CSF culture yielded S. pneumoniae in a
higher proportion of episodes with hyperglycemia as
compared with normal glucose levels. Interestingly,
patients with hyperglycemia were less likely to present
sign of systemic compromise: smaller proportions pre-
sented with a diastolic blood pressure <60 mm Hg, or CSF
white blood cell counts <1000 cells/mm3, and they had
higher platelet counts. CSF glucose levels were measured
in 617 patients (89%) and correlated with blood glucose
levels (Pearson's, P < 0.001). Median glucose CSF/serum
ratio was 0.09 (IQR, 0.02–0.31) for patients with favora-
ble outcome (GOS score 5, n = 459), and 0.05 (IQR, 0.01–
0.21) for patients with unfavorable outcome (GOS score
< 5, n = 237; P = 0.01). No statistically significant differ-
ence in glucose CSF/serum ratio was seen between
patients who died (n = 143) and those who survived (n =
553, P = 0.24).
The overall number of patients with an unfavorable out-
come was 228 (33%). Mortality was significantly higher
in severely hyperglycemic patients (26% vs. 19%, P =
0.05). This association remained significant after exclu-
sion of patients with a preadmission diagnosis of diabetes
(40% vs. 30%, P = 0.03).
We performed a univariate analysis on the raw dataset,
followed by a multivariate regression analysis to identify
factors predictive for unfavorable outcome (Table 2). We
also included serum glucose in this model. We identified
several (known) factors for unfavorable outcome: S. pneu-
moniae as the causative microorganism, advanced age, a
low score on the Glasgow Coma Scale, the presence of a
focal neurologic deficit, a low platelet count and a low
CSF leukocyte count. In the multivariate analysis serum
glucose was no longer predictive of outcome.
As a next step we undertook a multivariate analysis of fac-
tors related to blood glucose levels. The following factors
were associated with a rise of serum glucose: a preadmis-
sion diagnosis of diabetes (an extra 5.30 mmol/L or 95.36
mg/dL of glucose if present), age (every year added an
extra 0.02 mmol/L or 0.31 mg/dL of glucose, P = 0.03),
the presence of a distant focus of infection (an extra 0.88
mmol/L or 15.77 mg/dL of glucose if present, P = 0.004),
the presence of immunocompromised states other than
diabetes (an extra 0.99 mmol/L or 17.84 mg/dL of glucose
if present, P = 0.03), diastolic blood pressure (every 1 mm
Table 1: Features in adults with and without hyperglycemia or severe hyperglycemia











Age 44 (24–64) 55 (37–68) <0.001 48 (29–65) 59 (45–70) <0.0001
Seizures 2/206 (1%) 29/447 (7%) 0.001 20/493 (4%) 11/160 (7%) 0.2
Distant infection focus 
*
60/212 (28%) 175/470 (37%) 0.02 155/511 (30%) 80/171 (47%) <0.001
Diabetes 6/210 (3%) 40/466 (9%) 0.005 14/506 (3%) 32/170 (19%) <0.001
Immunocompromised 26/211 (12%) 83/470(18%) 0.09 62/510 (12%) 47/171 (28%) <0.001
GCS <14 127/211 (60%) 342/469 (73%) 0.001 327/510 (64%) 142/170 (84%) <0.001
GCS <8 (coma) 17/211 (8%) 77/469(16%) 0.004 58/510 (11%) 36/170 (21%) 0.002
DBP < 60 mmHg 32/201 (16%) 29/457 (6%) <0.001 58/490 (12%) 3/168 (2%) <0.001
HR > 120 bpm 27/212 (13%) 48/470 (10%) 0.3 53/511 (10%) 22/171 (13%) 0.4
T >38.0 154/200 (77%) 357/465(77%) 1.0 380/496 (77%) 131/169 (94%) 0.8
Focal neurologic 
deficits#
67/212 (32%) 161/470 (34%) 0.5 162/511 (32%) 66/171 (39%) 0.1
S. pneumoniae 88/212 (42%) 256/470 (55%) 0.007 228/511 (45%) 116/171 (68%) <0.001
CSF white cell count 
<1000
58/197 (29%) 76/436 (17%) 0.001 104/474 (22%) 30/159 (19%) 0.4
Platelet cell count 175 (121–237) 189 (147–240) 0.03 180 (139–236) 198 (150–253) 0.02
Positive blood culture 121/178(68%) 276/424 (65%) 0.5 295/447(66%) 102/155 (66%) 1.0
Unfavorable outcome 65/212 (31%) 163/470 (35%) 0.3 156/511 (31%) 72/171 (42%) 0.008
Mortality 38/212 (18%) 102/470 (22%) 0.3 96/513 (19%) 44/169 (26%) 0.05
Numbers are number/number assessed (percentage) or median (interquartile range) unless otherwise indicated. GCS denotes Glasgow Coma 
Scale, DPB diastolic blood pressure, HR hear rate, T bodily temperature (grade Celsius), CSF cerebrospinal fluid. * Defined as otitis/sinusitis or 
pneumonia. #Defined as cranial nerve palsies, aphasia, monoparesis or hemiparesisPage 3 of 7
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P < 0.001), sum score on the Glasgow Coma Scale (every
decrease by one point added an extra 0.15 mmol/L or 2.77
mg/dL of glucose, P < 0.001) and CSF leukocyte count
(every 10-fold decrease added an extra 0.16 mmol/L or
2.86 mg/dL of glucose, P < 0.001). Platelet counts or infec-
tion with S. pneumoniae were not related to blood glucose
levels in this analysis
A preadmission diagnosis of diabetes was present in 46
patients (Table 3); 87% of these patients were hyperglyc-
emic on admission and 70% were severely hyperglycemic.
The median age was 69 years and predisposing conditions
other than diabetes were present in a large proportion of
patients (39%). Patients had severe illness as reflected in
low levels of consciousness and high rates of focal neuro-
logic deficits. Overall, the clinical presentation was not
"atypical" (i.e., lacking the "classical" clinical symptoms
of fever, headache and a decreased level of consciousness)
and the vast majority of patients had pneumococcal men-
ingitis (67%). Other causative organisms were Listeria
monocytogenes (13%), group B streptococci (4%), and
Escherichia coli (2%). The rate of unfavorable outcome
among diabetic patients was high (52%).
Table 2: Univariate and Multivariate analysis of factors associated with unfavorable outcome
Characteristic Odds ratio (95% CI) (univariate) P Odds ratio (95% CI) (multivariate) P
Age, yrs 1.47 (1.35–1.62) <0.0001 1.16 (1.03–1.16) 0.01
Known diabetes 2.24 (1.23–4.11) <0.01 0.96 (0.42–2.16) 0.9
Immunocompromised, not diabetes 2.92 (1.76–4.90) <0.0001 1.15 (0.61–2.17) 0.7
Heart rate
< 60 bpm 2.26 (0.73–6.58) <0.01 4.95 (1.09–22.45) 0.04
60–90 bpm 1.00 (reference) 1.00 (reference)
>90–120 bpm 1.62 (1.09–2.44) 1.23 (0.75–2.01) 0.4
>120 bpm 3.96 (2.51–6.31) <0.001 2.44 (1.35–4.43) 0.003
Diastolic blood pressure 0.97 (0.92–1.01) 0.01 0.95 (0.90–1.01) 0.09
Glasgow Coma Scale 0.82 (0.78–0.86) <0.001 0.87 (0.81–0.93) <0.001
Distant focus of infection* 2.05 (1.48–2.84) <0.0001 1.04 (0.67–1.63) 0.9
Focal neurologic deficits# 2.50 (1.80–3.48) <0.0001 1.93 (1.28–2.90) 0.002
Blood glucose 0.87 (0.69–1.07) 0.001 0.93 (0.75–1.16) 0.5
Log platelet count 0.62 (0.50–0.76) <0.001 0.62 (0.48–0.81) <0.001
Log CSF leukocyte count 0.80 (0.75–0.85) <0.001 0.80 (0.74–0.87) <0.001
Causative organism
S. pneumoniae 7.65 (5.02–12.00) <0.0001 4.95 (2.69–9.12) <0.001
N. meningitidis 1.00 (reference) 1.00 (reference)
Other 3.98 (2.22–7.17) <0.001 2.38 (1.12–5.04) 0.02
* Defined as otitis/sinusitis or pneumonia. # Defined as cranial nerve palsies, aphasia, monoparesis or hemiparesis. Bpm denotes beats per minute, 
CSF cerebrospinal fluid.
Table 3: Characteristics of diabetic patients with meningitis (n = 46)
Characteristics value Characteristics value
Median age in years (IQR) 69 (59–74) Laboratory features
Symptoms <24 hours 30/45 (65%) CSF WBC <1000/mm3 10/46 (23%)
Predisposing conditions Blood glucose ≥ 7.8 mmol/L (≥ 140 mg/dL) 40 (87%)
Distant focus of infection* 33/46 (72%) Blood glucose ≥ 11.1 mmol/L (≥ 200 mg/dL) 32 (70%)
Otitis/sinusitis 15/46 (33%) Positive blood culture 25/46 (57%)
Pneumonia 5/46 (11%) Causative organism
Symptoms and signs S. pneumoniae 31/46 (67%)
Headache 33/41 (81%) N. meningitidis 6/46 (13%)
Neck stiffness 34/44 (77%) Listeria monocytogenes 6/46 (13%)
Temperature >38°C 38/46 (83%) Group B streptococci 2/46 (4%)
GCS <14 35/45 (78%) Escherichia coli 1/46 (2%)
Score on GCS <8 14/44 (31%) Favorable outcome 22/46 (48%)
Focal neurologic deficits# 24/46 (52%) Death 15/46 (33%)
* Defined as otitis/sinusitis or pneumonia. # Defined as cranial nerve palsies, aphasia, monoparesis or hemiparesis. IQR denotes interquartile rate, 
GCS Glasgow Coma Scale, WBC white blood cell countPage 4 of 7
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Our study shows that hyperglycemia is a very common
finding in patients presenting with bacterial meningitis.
One out of four patients in our cohort had severe hyperg-
lycemia which was related with unfavorable outcome in a
univariate analysis (P = 0.008). However, the association
between glucose levels and unfavorable outcome did not
remain robust in a multivariate analysis.
Many of the factors predictive for unfavorable outcome
were also predictive for severe hyperglycemia on admis-
sion. High blood glucose levels seem to be an epiphenom-
enon of disease severity and physical stress, at least partly.
Factors predictive for systemic compromise are strong pre-
dictors of unfavorable outcome in adults with bacterial
meningitis.[8] This relation is comparable with any other
critical illness. However, some of the well known factors
predictive for unfavorable outcome in bacterial meningi-
tis, such as low CSF white cell counts, low diastolic blood
pressure, and low thrombocyte counts, were not related to
high glucose serum levels. On the contrary, these factors
had an inverse relation with serum blood glucose levels.
This finding could not be explained by differences in caus-
ative bacterial agents between groups. Our results there-
fore emphasize the importance of the insult to the central
nervous system, rather than the systemic insult in patients
with bacterial meningitis, leading to disturbed blood-glu-
cose regulation mechanisms. This effect has been
described previously in patients after stroke and might be
caused by effects on central autonomic control
sites.[16,17]
Diabetes was by far the strongest predictor for higher glu-
cose levels on admission. The overall proportion of
patients with a pre-admission diagnosis of diabetes was
7%. However, this percentage might have been underesti-
mated since many patients had diabetic blood glucose lev-
els on admission. The incidence of diabetes among adults
with bacterial meningitis has been reported to be as high
as 39% in Taiwan.[18] The meningitis population in Tai-
wan differed markedly from our cohort with respect to the
causative organisms. In Taiwan, Klebsiella pneumoniae was
the most common causative organism in both diabetic
and non-diabetic patients, whereas no infection with S.
pneumoniae occurred in any of the diabetic patients. By
contrast, in our cohort S. pneumoniae was the most com-
mon causative microorganism and was significantly more
common in patients with hyperglycemia (55%) than in
patients without hyperglycemia (42%). Differences in
microbial epidemiology, innate immunity and health
care might account for these differences.
As in stroke, hyperglycemia could be a measure of previ-
ously unrecognized insulin resistance or diabetes.[19]
This idea is supported by the observation that predictors
for hyperglycemia were also associated with diabetes
before admission: older age, other immunocompromise
than diabetes (use of immunosuppressive medication,
like corticosteroids), and a distant focus of infection.
The majority of patients with a pre-admission diagnosis of
diabetes had pneumococcal meningitis (67%). Diabetes
is a well known risk factor for invasive pneumococcal dis-
eases. In the U.S. and some European countries, physi-
cians are advised to vaccinate diabetic patients with the
23-valent pneumococcal polysaccharide vaccine [20-22].
The 23-valent pneumococcal polysaccharide vaccine
would have provided coverage for 87% of all causative
pneumococcal strains in the Dutch Meningitis Cohort
Study.[23] Vaccine efficacy however, is likely less than
60%[24] and no randomized controlled clinical trials
using this vaccine have yet been carried out in diabetic
patients to support this recommendation.
This study has several limitations. First, only patients who
had a positive CSF culture were included. Negative CSF
cultures are estimated to occur in 11 to 30% of patients
with bacterial meningitis.[10,25] No significant differ-
ences in clinical presentation have been reported between
culture-positive bacterial meningitis and those with cul-
ture-negative bacterial meningitis.[25,26] It is therefore
unlikely that this factor confounded our results. Second
but more importantly, we used a single random blood
glucose measurement on admission to define hyperglyc-
emia. As can be seen in stroke[27] and subarachnoid hem-
orrhage[3], persistent hyperglycemia or persistently high
levels of fasting blood glucose may be more important
than hyperglycemia on admission and might have an
independent effect on outcome, which we were not able
to assess because follow-up blood glucose concentrations
were unavailable. We also did not measure glycosylated
hemoglobin (HbA1C) in our patients. This is an impor-
tant limitation of our study. Finally, we have no data on
the adequacy of antihyperglycemic treatment and treat-
ment-related hypoglycemia.
Although the exact nature of the relation between severe
hyperglycemia and outcome in bacterial meningitis
remains uncertain, data of previous studies including crit-
ically ill patients suggest that severe hyperglycemia should
be treated, also in adults presenting with bacterial menin-
gitis. Based on these previous studies, we recommend
aiming for blood glucose levels below 10.0 mmol/L (180
mg/dL) throughout the clinical course, while trying to
avoid hypoglycemia. The increased risk of hypoglycemia
has been one of the major concerns put forward with
regard to intensive insulin therapy.[28] A recently pub-
lished study even found an increased mortality and a
higher incidence of hypoglycemia in critically ill patients
who where treated with intensive glucose control as com-Page 5 of 7
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cose control.[29] Although we were unable to assess the
frequency and severity of treatment-related hypoglycemia
in our cohort, hypoglycemia can be life threatening and
hypoglycemic symptoms are not easily recognized in
patients with acute bacterial meningitis. Severe hypoglyc-
emia or prolonged hypoglycemia can lead to convulsions,
coma, and irreversible brain damage. In the single-center
prospective randomized controlled trials from Leuven,
the risk of hypoglycemia (glucose of ≤ 2.2 mmol/L or ≤ 40
mg/dL) increased from 0.8% to 5.1% in the surgical ICU
trial and from 3.1% to 18.7% in the medical ICU
trial.[7,8] In those ICU based trials, insulin adjustments
were based on measurements of blood glucose levels in
arterial blood, at one- to four-hour intervals, and doses
were administered by a team of intensive care nurses,
assisted by a study physician. The question arises whether
intensive insulin therapy is feasible, safe and effective
when implemented outside of the ICU, where most
patients with acute bacterial meningitis are managed. Pre-
vious studies have shown that control of hyperglycemia in
patients admitted to a stroke unit remains difficult.[19]
However, in light of the growing evidence of the detri-
mental effects of sustained hyperglycemia in other neuro-
logical diseases, physicians treating patients with bacterial
meningitis should play a more active role in the control of
blood glucose levels.
Conclusion
The majority of patients with bacterial meningitis have
hyperglycemic blood glucose levels on admission. Hyper-
glycemia can be explained by a physical stress reaction,
the central nervous system insult leading to disturbed
blood-glucose regulation mechanisms, and preponder-
ance of diabetics for pneumococcal meningitis. Patients
with diabetes and bacterial meningitis are at high risk for
unfavorable outcome.
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